Fate Therapeutics Inc (FATE)
| Market Cap | 249.23M+37.8% |
| Revenue (ttm) | 6.49M |
| Net Income | -126.00M |
| EPS | -1.05 |
| Shares Out | 119.82M |
| PE Ratio | n/a |
| Forward PE | -2.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,897 |
| Open | 2.12 |
| Previous Close | 2.15 |
| Day's Range | 2.06 - 2.12 |
| 52-Week Range | 0.95 - 3.23 |
| Beta | 2.53 |
| Analysts | Buy |
| Price Target | 5.74(+176.17%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$FATE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in FATE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FATE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FATE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FATE Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Less: | $33.22M | 56.67% |
| Personnel costs | $10.66M | 18.18% |
| Clinical programs | $7.43M | 12.68% |
| Facilities costs | $4.24M | 7.23% |
| Collaboration revenue | $2.08M | 3.55% |
| Research activities | $991.00K | 1.69% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FATE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FATE from public contracts
Source: USAspending.gov
FATE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from FATE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score